Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

NCT07201675 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Cancer (MIBC)

Interventions

DRUG: RC48-ADC combined with toripalimab for bladder-sparing therapy

Sponsor

Qilu Hospital of Shandong University